99 results about "Live vector vaccine" patented technology

The invention relates to a recombinant fusion protein vaccine and an attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection, and belongs to the field of biopharmaceutics. The recombinant fusion protein vaccine and the attenuated live vector vaccine for expressing the recombinant fusion protein are characterized in that: the recombinant fusion protein is formed by connecting immune protective function fragments of helicobacter pylori cytotoxin relevant gene protein CagA from helicobacter pylori, vacuolization cytotoxin VacA and urease subunit UreB linearly, and the immunogenicity and immune protection of the recombinant fusion protein are verified through animal experiments. The live vaccine has the advantages that: 1, an Hp fusion protein gene can beexpressed stably; 2, mucosa and systemic immune response can be induced after immunity; and 3, the method is convenient, the cost is low, and the economic benefit is obvious. Therefore, the attenuated live vector vaccine can be used as candidate vaccines for treating and preventing the Hp infection.

The invention relates to a peste des petits ruminants virus (PPRV) reverse genetic operating system and an application thereof. The PPRV reverse genetic operating system comprises a transcription plasmid and one or more helper plasmids, wherein the transcription plasmid can express the genome full-length cDNA (complementary deoxyribonucleic acid) sequence of the PPRV; and the helper plasmid(s) can express nucleoprotein (N), phosphoprotein (P) and polymerase large protein (L) of the PPRV, and virus replication-permitting host cells of the PPRV. By using the PPRV reverse genetic operating system, the recombined PPRV is successfully saved. The establishment of the PPRV reverse genetic operating technical platform provides an excellent technical platform for the development of PPRV live vector vaccines and the fundamental research related to PPRV.

The present invention relates to novel plasmid constructs useful for the delivery of DNA vaccines. The present invention provides novel plasmids having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The present invention, however, is particularly useful for inducing in a patient an immune response against pathogenic viruses such as HIV, measles or influenza. Immunodeficiency virus vaccine inserts of the present invention express non-infectious HIV virus-like particles (VLP) bearing multiple viral epitopes. VLPs allow presentation of the epitopes to multiple histocompatability types, thereby reducing the possibility of the targeted virus escaping the immune response. Also described are methods for immunizing a patient by delivery of a novel plasmid of the present invention to the patient for expression of the vaccine insert therein. Optionally, the immunization protocol may include a booster vaccination that may be a live vector vaccine such as a recombinant pox virus or modified vaccinia Arbora vector. The booster live vaccine vector includes a transcription cassette expressing the same vaccine insert as the primary immunizing vector.

The invention discloses a salmonella enteritidis double knockout attenuated mutant and preparation as well as application thereof. The salmonella enteritidis double knockout attenuated mutant is obtained by knocking out crp gene and spiC gene of salmonella enteritidis C50041. The invention further discloses a preparation method as well as application of the salmonella enteritidis double knockout attenuated mutant. Further attenuation of the salmonella enteritidis attenuated mutant is realized. A foundation is laid for researching salmonella enteritidis attenuated live vaccines and live vector vaccines.

This invention supplies a series of production techniques of gene recombination live vaccine of swine virus contagion with canine ó� adenovirus as carrier and finished goods. The viral live vectors vaccine takes swine important virus zymad protective antigens gene as object gene, which are chosen from HCV-E1, E2 gene, FMDV-VP1íóVP2íóVP3íóVP4 gene, TGEV-SíóNíóM gene, PEDV-SíóNíóM geneú¼SIV-HAíóNA geneú¼RV-GíóN gene, etc. The produced vaccines contain recombined swine influenza virus HA gene adenovirus carrier live vaccine, swine plague virus E2 gene adenovirus carrier live vaccine and recombination swine AsiaI foot-and-mouth disease virus VPI gene adenovirus carrier live vaccine. Recombination virus has good inheritance stability, and vaccine immunization can induct pig develop differential antiviral neutralization antibody. It has good immune protection effect and has no toxic side effect. The goods are facilitating for preserve and transportú”it has long storage life and simple technics, and it fits for commercial manufacture.

The invention provides an expression vector used for expressing foreign protein in the recombination of goat pox virus. A foreign gene is inserted in the down stream of a VVI1L promoter or a VVP11 promoter in the expression vector, by the homologous recombination with the parent plant of the goat pox virus, 12 recombined sheep pox viruses for expressing the foreign protein are obtained, a flanking sequence in the vector, which can make the homologous recombination with the parent plant of the goat pox virus, is a sheep pox virus G14-STV-44-55 vaccine strain which contains TK gene, IFNR-gamma gene or RR small subunit gene, by utilizing the expression vectors, the recombined goat pox viruses expressing different foreign proteins can be constructed by different methods, and the recombined goat pox viruses can be used as recombined live vector vaccines to prevent and treat diseases and study relations of expression, processing, structure and function of different biological active proteins.

The invention relates to a multivalent Clostridium difficile vaccine comprising a Salmonella Typhi live vector comprising the cell binding domain of TcdA toxin (CBD / A) of Clostridium difficile or an antigenic fragment thereof and the cell binding domain of TcdB toxin (CBD / B) of Clostridium difficile or an antigenic fragment thereof and optionally the cell-binding subunit component (CdtB) of binary toxin of Clostridium difficile or an antigenic fragment thereof. The invention further provides methods of inducing an immune response and methods of preventing recurrence of C. difficile infections in subjects.

The invention discloses a recombinant Newcastle disease virus for expressing goose parvovirus VP3 genes and a construction method thereof, belonging to the field of recombinant virus vaccines. The recombinant Newcastle disease virus is a goose isolate, the cleavage site amino acid sequence of F protein of the recombinant Newcastle disease virus is GRQGRL, and the P3 gene is positioned in a noncoding region between the P gene and M gene of Newcastle disease virus. The transcription plasmid pCI-NA-VP3(SEQ ID NO.1) and the transcription helper plasmid pcDNA-N, pcDNA-P and pcDNA-L(SEQ ID NO. 2-4) cotransfect a host cell licensed by application of the Newcastle disease virus to culture a transfected host cell, and the recombinant Newcastle disease virus can be saved from a cell suspension of the transfected host cell. The recombinant Newcastle disease virus for expressing goose parvovirus VP3 genes can be used as a bivalent living-vector vaccine for preventing Newcastle disease virus and goose parvovirus.

The present invention relates to replicative live AIDS carrier vaccine expressing HIV antigen and its use. The vaccine is constructed based on replicative vaccinia virus, such as vaccinia virus Tiantan strain. The replicative live AIDS carrier vaccine can induce high level HIV resisting body fluid and cellular immune response. The present invention provides the carrier for constructing the AIDS vaccine, and also relates to immunizing process with the AIDS vaccine.

The invention provides a live vector vaccine for expressing a peste des petits ruminants virus (PPRV) H gene and a preparation method thereof. In the invention, the prepared recombinant virus has good genetic stability so that a goat can be induced to generate a specific antiviral neutralizing antibody after being immunized by the vaccine prepared from the virus. The live vector vaccine has the advantages of good immune protective effect, no toxic side effect, long shelf life and simple production process, and is easy for preservation and convenient for transportation, thus being applicable to industrialized production.

The invention discloses a preparation method of a live vector vaccine for controlling chicken coccidiosis, comprising the following steps of obtaining a recombinant expression vector by connecting a mature peptide of an eimeria tenella sporozoite antigen gene 3-1E gene and an expression vector of bacillus subtilis, obtaining a recombinant strain by transferring the recombinant expression vector into a bacillus subtilis host, and culturing the recombinant strain to finally obtain the live vector vaccine for controlling the chicken coccidiosis by. The live vector vaccine can be used for controlling and / or treating the chicken coccidiosis. The invention also discloses an oral biological preparation for controlling the chicken coccidiosis, prepared by utilizing the live vector vaccine. The oral biological preparation comprises the live vector vaccine and a vector. The oral biological preparation per gram contains the live vector vaccine with a living bacteria number of 108-109cfu.

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a living-vector vaccine of an H5N1 subtype of avian influenza virus and a duck enteritis virus. A vaccine strain rDEV-HA5 is preserved at the typical culture preservation centre in China, wherein the preservation number is CCTCC NO:V201404. The building method disclosed by the invention comprises the following steps: inserting a segment of an H5N1 subtype of avian influenza virus ha gene into an artificial chromosome plasmid pBAC-C-KCE of the duck enteritis virus, so as to obtain recombinant plasmids pBAC-C-KCE-HA5, wherein the gene structure composition of the plasmid pBAC-C-KCE is shown in a figure 7; the gene structure composition of the plasmids pBAC-C-KCE-HA5 is shown in a figure 14. Biological function verification proves that the vaccine disclosed by the invention has the effect of simultaneously preventing duck enteritis and the H5N1 subtype of avian influenza, and can achieve the target of simultaneously preventing two diseases by a needle.

The invention discloses a salmonella enteritidis strain with ssrAB gene deletion. The strain is obtained after knockout of altogether 915 base pairs, from amino acid located at site 689 of ssrA gene to amino acid located at site 63 of ssrB gene. The invention further discloses a construction method for the salmonella enteritidis strain with ssrAB gene deletion. The construction method comprises the following steps: (1) acquiring SN and SC genes of ssrAB and connecting upstream and downstream homologous arms through overlap PCR; (2) constructing recombinant suicide plasmid pWM91-ssrAB; (3) carrying out solid phase joint of bacteria; and (4) screening and acquiring G9-2012 (delta ssrAB). The invention has the following beneficial effects: the G9-2012 (delta ssrAB) strain has a decreased colonization rate and obviously weakened virulence in vivo, can be used for development of attenuated live vaccine or live vector vaccine against salmonella enteritidis, and thus reduces the rate of infection of human beings or animals by salmonella enteritidis and guarantees health of the mankind.

The invention discloses a recombination attenuated salmonella typhimurium carrier vaccine of expression IBDV (Infectious Bursal Disease Virus) immunogenic gene, a preparation method and application thereof, in particular relates to oral attenuated salmonella typhimurium. The recombination attenuated salmonella typhimurium comprises a sequence disclosed by SEQ ID NO.1, and the recombination virus can express IBDV capsid protein VP2. The preparation method comprises the following steps of: inoculating the attenuated salmonella typhimurium in an LB substrate for culturing 18 hours; regulating bacterial concentration as 1010CFU / ml; and preparing the safe and effective oral attenuated salmonella typhimurium carrier vaccine for preventing IBD (Infectious Bursal Diseases).

The invention relates to a replicating type AIDS live vector vaccine expressing a human immunodeficiency virus (HIV) antigen and application thereof. The vaccine is constructed based on a replicatingtype vaccinia virus such as a vaccinia virus Tiantan strain. The replicating type AIDS live vector vaccine can induce high-level anti-HIV humor immune response and cellular immune response, and provides a vector for constructing the AIDS vaccine. The invention also relates to an immunization scheme using the AIDS vaccine.

The present invention relates to a PRRSV and PCV-2 bivalent recombinant fowlpox live vector vaccine, which pertains to the field of biotechnology. The present invention aims at providing the PRRSV and PCV-2 bivalent recombinant fowlpox live vector vaccine which has ORF5, ORF3 genes to express the structural glycoprotein of the PRRSV and ORF2 gene to express PCV-2 nucleocapsid protein and can be used as the live vector vaccine for the prevention of PRRS and PCV-2 infection in our country. The present invention constructs the pMD18T-ORF2, pMD18T-ORF5 and pMD18T-ORF3 plasmids, the plasmids are inserted to the downstream of the compound promoter ATI-P7.5 multiplied by 20 of the fowlpox virus expression vector pUTAL, at the same time, the ORF2 gene of the PCV2 are inserted to the downstream of the linking promoter P7.5 multiplied by 16, and the present invention further constructs the recombinant fowlpox virus gene transfer plasmid pUTAL-ORF2-ORF5-ORF3 which contains the ORF3-ORF3 gene of the PRRSV and the ORF2 gene of the PCV2. The present invention can be used as the live vector vaccine for the prevention of PRRS-PCV2 in our country.

The invention relates to a Newcastle disease virus rNDV-H52AH9, accession number CGMCC (China General Microbiological Culture Collection Center) No: 6654. An attenuated strain AI4 of the Newcastle disease virus is used as a carrier, HA genes of H5 and H9 subtype avian influenza virus are connected in series through FMDV (Foot and mouth disease virus) 2A and are inserted into the genome AI4 containing full-length transcript carrier pNDV / AI4 to obtain recombinant NDV genome full-length clone pNDV / AI4-H52AH9. The recombinant virus rNDV-H52AH9 is obtained by reverse genetic operation, has higher reproductive titer on embryonated eggs, and simultaneously expresses the HA protein of H5 and H9 subtype avian influenza virus stably, and lays a foundation for the development and application of multi-joint recombinant live vector vaccine of AI and ND.

The invention belongs to the technical field of biology, and mainly relates to a recombinant fowlpox virus transfer vector expressing a fowl adenovirus serotype-4 (FADV4) fiber2 gene, a constructing method thereof and applications of the transfer vector. A pMD19T-Simple vector is adopted as a base of the transfer vector. The FADV4 fiber2 gene, a lacz gene, and fowlpox virus genome replicated non-essential fragments which are LTYB and RTYB used for homologous recombination are inserted in a TA cloning site. The method includes constructing a plasmid pMD-TYB; constructing a plasmid pMD22; constructing a plasmid pMD22-lacz; constructing an intermediate vector pMD22-TYB-lacz; amplifying the FADV4 fiber2 gene; constructing a recombinant fowlpox virus transfer vector pMD22-TYB-lacz-F4; subjecting a chicken embryo Fibroblast to cotransfection with the transfer vector pMD22-TYB-lacz-F4 and a fowlpox virus; performing identification to select a positive product; performing subculture continuously; and identifying expression effects of the recombinant fowlpox virus. The recombinant fowlpox virus transfer vector constructed by the method lays a foundation for development of an efficient recombinant fowlpox virus genetic engineering living-vector vaccine expressing the fowl adenovirus serotype-4.